Avelumab

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Osteosarcoma

Conditions

Osteosarcoma

Trial Timeline

Feb 16, 2017 → Mar 18, 2020

NCT ID

NCT03006848

About Avelumab

Avelumab is a phase 2 stage product being developed by Pfizer for Osteosarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03006848. Target conditions include Osteosarcoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05568407	Pre-clinical	Terminated	Jan 18, 2023	Jun 16, 2023	Bladder Cancer
NCT03617666	Phase 2	UNKNOWN	Sep 27, 2019	May 30, 2025	Hodgkin Lymphoma
NCT03719768	Phase 1	Completed	Jun 10, 2019	Aug 21, 2024	Leptomeningeal Metastases
NCT03774901	Phase 2	UNKNOWN	Mar 12, 2019	Sep 22, 2024	Penile Cancer
NCT03498196	Phase 1/2	Terminated	Dec 14, 2018	Dec 9, 2019	Bladder Cancer
NCT03395873	Phase 1	Terminated	Jan 29, 2018	May 15, 2019	Acute Myeloid Leukemia
NCT03267836	Phase 1	Terminated	Jan 10, 2018	Apr 6, 2023	Meningioma
NCT03399552	Phase 1/2	Completed	Dec 20, 2017	Jan 20, 2023	Malignant Mesothelioma (MPM)
NCT03046953	Phase 2	Completed	Dec 8, 2017	Jul 27, 2021	T-Cell Lymphoma Relapsed
NCT03050554	Phase 1/2	Terminated	Oct 26, 2017	Oct 7, 2019	Early Stage Non-Small Cell Lung Cancer
NCT03006848	Phase 2	Completed	Feb 16, 2017	Mar 18, 2020	Osteosarcoma
NCT02875613	Phase 2	Terminated	Jan 1, 2017	Apr 1, 2019	Nasopharyngeal Cancer
NCT02952586	Phase 3	Terminated	Nov 28, 2016	Aug 25, 2020	Squamous Cell Carcinoma of the Head and Neck

Competing Products

18 competing products in Osteosarcoma

See all competitors

Product	Company	Stage	Hype Score
Azenosertib + Gemcitabine	Zentalis Pharmaceuticals	Phase 1/2	33
Lenvatinib + Ifosfamide + Etoposide + Lenvatinib	Eisai	Phase 2	52
Pemetrexed	Eli Lilly	Phase 2	52
pemetrexed	Eli Lilly	Phase 2	52
Camrelizumab in Combination With Neoadjuvant Chemotherapy	Jiangsu Hengrui Medicine	Phase 2	52
Apatinib	Jiangsu Hengrui Medicine	Phase 2	52
Olaparib + Ceralasertib	AstraZeneca	Phase 2	52
Saracatinib + Placebo	AstraZeneca	Phase 2	52
robatumumab	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
pazopanib	Novartis	Phase 2	52
Nivolumab + Azacitidine	Bristol Myers Squibb	Phase 1	32
Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 2	51
Cisplatin liposomal	Insmed	Phase 1/2	38
Cabozantinib	Ipsen	Phase 2	49
Sm-EDTMP	Jazz Pharmaceuticals	Phase 2	49
LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).	Lantheus Holdings	Phase 1/2	38
REOLYSIN®	Oncolytics Biotech	Phase 2	44

Other Products from Pfizer